LTS Lohmann Therapie-Systeme

Executive Summary

LTS Lohmann Therapie-Systeme AG is a privately held German drug delivery CDMO, established in 1984 and headquartered in Andernach. The company specializes in non-invasive delivery technologies, including transdermal patches, oral thin films, and micro-array patches (MAPs). LTS provides end-to-end services from R&D to commercial manufacturing, partnering with pharmaceutical companies to enhance patient compliance and therapeutic outcomes. With over four decades of experience, LTS has built a strong reputation in the drug delivery space, focusing on innovative solutions that address unmet needs in areas such as central nervous system disorders, pain management, and hormonal therapies. The company's proprietary platforms enable the delivery of complex molecules, including biologics and vaccines, via minimally invasive routes. As a CDMO, LTS benefits from the growing outsourcing trend in pharma, particularly for specialized delivery technologies. The company's financials are not publicly disclosed, but its sustained operation and partnerships with major pharma firms underscore its market relevance. However, being private, LTS faces challenges in visibility and capital access compared to publicly traded peers.

Upcoming Catalysts (preview)

• Q3 2026Announcement of a major CDMO contract for micro-array patch platform60% success
• Q1 2027FDA approval of an oral thin film product developed with a partner40% success
• H2 2026Expansion of manufacturing capacity or new technology licensing deal50% success